Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Risperidone-induced Symptomatic Hyperprolactinaemia in Adolescents

Holzer, Laurent MD*; Eap, Chin B. PhD

Journal of Clinical Psychopharmacology: April 2006 - Volume 26 - Issue 2 - p 167-171
doi: 10.1097/
Brief Reports

Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea. However, the largest study performed in children and adolescents showed a weak effect of risperidone on prolactin concentrations during short-term treatment and a negligible effect during long-term treatment, which was probably because of the relatively low dosages of risperidone used [~0.04 mg/(kg · d)]. Among the 10 psychotic adolescents treated with risperidone in our unit, we had 3 cases of gynecomastia in 3 male patients and 2 cases of galactorrhea in 2 female patients. The prolactin blood levels in these cases and in 3 other patients without apparent prolactin-related side effects were all above the normal range (median, 59 ng/mL; range, 30-123 ng/mL). Thus, risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Given that the long-term effects of antipsychotic drug-induced hyperprolactinemia are not well documented, especially regarding osteopenia, infertility, growth, and pubertal delay, risperidone should be administered with caution to children and adolescents.

(J Clin Psychopharmacol 2006;26:167-171)

*Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Centre Thérapeutique de Jour pour Adolescents, Lausanne, Switzerland; and †Unité de Biochimie et Psychopharmacologie Clinique, Centre de Neurosciences Psychiatriques, Département Universitaire de Psychiatrie Adulte, Hôpital de Cery, Prilly, Switzerland.

Received July 1, 2005; accepted after revision October 28, 2005.

Address correspondence and reprint requests to Laurent Holzer, MD, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Centre Thérapeutique de Jour pour Adolescents, Av de Beaumont 48, 1012 Lausanne, Switzerland. E-mail:

© 2006 Lippincott Williams & Wilkins, Inc.